Multiparametric MRI Scoring System of the Pancreas for the Diagnosis of Chronic Pancreatitis
Temel Tirkes,Dhiraj Yadav,Darwin L Conwell,Xuandong Zhao,Anil K Dasyam,Vivek Gowdra Halappa,Aashish Patel,Zarine K Shah,Jordan Swensson,Naoki Takahashi,Sudhakar Venkatesh,Ashley Wachsman,Liang Li,Kristofer Jennings,Yunlong Yang,Phil A Hart,Stephen J Pandol,Walter G Park,Santhi Swaroop Vege,Mark Topazian,Paul R Territo,Scott A Persohn,Dana K Andersen,Evan L Fogel,Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
DOI: https://doi.org/10.1002/jmri.29594
2024-09-03
Abstract:Background: Ductal features alone may not offer high diagnostic sensitivity or most accurate disease severity of chronic pancreatitis (CP). Purpose: Diagnose CP based on multiparametric MRI and MRCP features. Study type: Prospective. Population: Between February 2019 and May 2021, 46 control (23 males, 49.3 ± 14.1 years), 45 suspected (20 males, 48.7 ± 12.5 years), and 46 definite (20 males, 53.7 ± 14.6 years) CP patients were enrolled at seven hospitals enrolled in the MINIMAP study. CP classification was based on imaging findings and clinical presentation. Field strength and sequences: 1.5 T. T1-weighted (T1W) spoiled gradient echo, T1 map with variable flip angle, dual-echo Dixon, secretin-enhanced MRCP before and after secretin infusion. Assessment: Dual-echo fat fraction (FF), T1 relaxation time, extracellular volume (ECV), T1 signal intensity ratio of the pancreas to the spleen (T1 score), arterial-to-venous enhancement ratio (AVR), pancreatic tail diameter (PTD), pancreas volume, late gadolinium enhancement, pancreatic ductal elasticity (PDE), and duodenal filling grade of secretin-enhanced MRCP were measured. Statistical tests: Logistic regression analysis generated CP-MRI and secretin-enhanced CP-SMRI scores. Receiver operating characteristics analysis was used to differentiate definite CP from control. Interobserver agreement was assessed using Lin's concordance correlation coefficient. Results: Compared to control, definite CP cohort showed significantly higher dual-echo FF (7% vs. 11%), lower AVR (1.35 vs. 0.85), smaller PTD (2.5 cm vs. 1.95 cm), higher ECV (28% vs. 38%), and higher incidence of PDE loss (6.5% vs. 50%). With the cut-off of >2.5 CP-MRI score (dual-echo FF, AVR, and PTD) and CP-SMRI score (dual-echo FF, AVR, PTD, and PDE) had cross-validated area under the curves of 0.84 (sensitivity 87%, specificity 68%) and 0.86 (sensitivity 89%, specificity 67%), respectively. Interobserver agreement for both CP-MRI and CP-SMRI scores was 0.74. Conclusion: The CP-MRI and CP-SMRI scores yielded acceptable performance and interobserver agreement for the diagnosis of CP. Evidence level: 1 TECHNICAL EFFICACY: Stage 2.